ABHD5 and liver cancer: Xu discovered that in hepatocellular carcinoma (HCC) tissues, the expression of ABHD5 is significantly downregulated, and this downregulation is notably correlated with poor prognosis in liver cancer patients, suggesting that ABHD5 is a novel therapeutic target.